摘要 |
<p>Biomarkers are provided that are predictive of a subject's responsiveness to a therapy comprising lenvatinib or a pharmaceutically acceptable salt thereof (e.g., lenvatinib mesylate). The biomarkers, compositions, and methods described herein are useful in selecting appropriate treatment modalities for a subject having cancer (e.g., thyroid cancer, kidney cancer), suspected of having cancer, or at risk of developing cancer.</p> |
申请人 |
EISAI R&D MANAGEMENT CO., LTD.;FUNAHASHI, YASUHIRO;KADOWAKI, TADASHI;MATSUI, JUNJI;SIMON, JASON S.;XU, LUCY |
发明人 |
FUNAHASHI, YASUHIRO;KADOWAKI, TADASHI;MATSUI, JUNJI;SIMON, JASON S.;XU, LUCY |